Avital Lev

739 total citations
20 papers, 386 citations indexed

About

Avital Lev is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Avital Lev has authored 20 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Avital Lev's work include Cancer-related Molecular Pathways (5 papers), Epigenetics and DNA Methylation (3 papers) and Cancer Cells and Metastasis (3 papers). Avital Lev is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Epigenetics and DNA Methylation (3 papers) and Cancer Cells and Metastasis (3 papers). Avital Lev collaborates with scholars based in United States, Israel and United Kingdom. Avital Lev's co-authors include Wafik S. El‐Deiry, David T. Dicker, Amriti R. Lulla, Marie D. Ralff, Yan Zhou, Cyril H. Benes, Lanlan Zhou, Varun V. Prabhu, Kerry S. Campbell and Michael Slifker and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Avital Lev

19 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Avital Lev United States 11 215 182 110 60 51 20 386
Diana Spiegelberg Sweden 14 308 1.4× 279 1.5× 93 0.8× 40 0.7× 61 1.2× 31 555
Hildegonda P. H. Naber Netherlands 6 270 1.3× 192 1.1× 92 0.8× 39 0.7× 51 1.0× 6 419
Alexis S. Lopez United States 6 226 1.1× 170 0.9× 103 0.9× 74 1.2× 29 0.6× 8 495
Federica Lorenzi United Kingdom 6 230 1.1× 192 1.1× 104 0.9× 26 0.4× 35 0.7× 8 372
Marina Chan United States 10 331 1.5× 200 1.1× 77 0.7× 32 0.5× 86 1.7× 16 534
Svetlana Miklikova Slovakia 12 202 0.9× 168 0.9× 117 1.1× 33 0.6× 19 0.4× 17 401
Jana Plavá Slovakia 8 164 0.8× 208 1.1× 137 1.2× 38 0.6× 19 0.4× 16 357
Ruping Yan China 12 365 1.7× 189 1.0× 174 1.6× 51 0.8× 45 0.9× 22 559
Oihana Iriondo Spain 7 347 1.6× 278 1.5× 161 1.5× 28 0.5× 32 0.6× 9 518
Ramon M. Cabrera United States 4 143 0.7× 147 0.8× 79 0.7× 68 1.1× 71 1.4× 4 329

Countries citing papers authored by Avital Lev

Since Specialization
Citations

This map shows the geographic impact of Avital Lev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avital Lev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avital Lev more than expected).

Fields of papers citing papers by Avital Lev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avital Lev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avital Lev. The network helps show where Avital Lev may publish in the future.

Co-authorship network of co-authors of Avital Lev

This figure shows the co-authorship network connecting the top 25 collaborators of Avital Lev. A scholar is included among the top collaborators of Avital Lev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avital Lev. Avital Lev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lulla, Amriti R., Yan Zhou, Marie D. Ralff, et al.. (2022). miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.. PubMed. 12(1). 315–326. 2 indexed citations
2.
Zhao, Shuai, Lanlan Zhou, David T. Dicker, et al.. (2021). Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports. 11(1). 20871–20871. 13 indexed citations
3.
Tian, Xiaobing, Nagib Ahsan, Amriti R. Lulla, et al.. (2021). P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9. Neoplasia. 23(3). 304–325. 17 indexed citations
4.
5.
Ralff, Marie D., Aakash Jhaveri, Lanlan Zhou, et al.. (2020). TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget. 11(42). 3753–3769. 17 indexed citations
6.
7.
8.
Lev, Avital, Amriti R. Lulla, Brian C. Ross, et al.. (2018). ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research. 16(5). 754–766. 22 indexed citations
9.
Tian, Xiaobing, Amriti R. Lulla, Shengling Zhang, et al.. (2018). Abstract 3954: Anti-cancer agent P306 restores p53 pathway through PUMA. Cancer Research. 78(13_Supplement). 3954–3954.
10.
Lulla, Amriti R., Michael Slifker, Yan Zhou, et al.. (2017). miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Research. 77(24). 6902–6913. 44 indexed citations
11.
Prabhu, Varun V., Amriti R. Lulla, Neel S. Madhukar, et al.. (2017). Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS ONE. 12(8). e0180541–e0180541. 30 indexed citations
12.
Wagner, Jessica, C. Leah B. Kline, Marie D. Ralff, et al.. (2017). Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 16(19). 1790–1799. 56 indexed citations
13.
Lev, Avital, Amriti R. Lulla, Jessica Wagner, David T. Dicker, & Wafik S. El‐Deiry. (2017). Abstract 1067: Anti-cancer efficacy of imipridones in pancreatic cancer: single agent ONC212 or combination of ONC201 with IGF1-R inhibition. Cancer Research. 77(13_Supplement). 1067–1067. 1 indexed citations
14.
Deihimi, Safoora, Avital Lev, Michael Slifker, et al.. (2017). BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 8(25). 39945–39962. 21 indexed citations
15.
Lev, Avital, Safoora Deihimi, Elena Shagisultanova, et al.. (2017). Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology & Therapy. 18(9). 694–704. 14 indexed citations
16.
Lev, Avital, Amriti R. Lulla, David T. Dicker, & Wafik S. El‐Deiry. (2017). Abstract 2102: ONC201 targets AR and AR-V7 signaling pathways, reduces PSA and synergizes with everolimus in castration resistant prostate cancer. Cancer Research. 77(13_Supplement). 2102–2102. 1 indexed citations
17.
Lev, Avital, Amriti R. Lulla, Jessica Wagner, et al.. (2017). Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 8(47). 81776–81793. 37 indexed citations
18.
Finnberg, Niklas K., Avital Lev, Sergei I. Grivennikov, et al.. (2017). Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget. 8(40). 66747–66757. 96 indexed citations
19.
Prabhu, Varun V., Joshua E. Allen, Dan Zhao, et al.. (2016). Abstract 2497: ONC201 targets cancer stem cells in colorectal, prostate and glioblastoma multiforme tumors via modulation of stem cell-related gene expression. Cancer Research. 76(14_Supplement). 2497–2497. 1 indexed citations
20.
Valansi, Clari, et al.. (1998). Cell cycle inhibition in human BE-13 T cell leukemia cells by haptoglobin-related (HPR) antisense cDNA.. PubMed. 18(3A). 1745–50. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diana Spiegelberg Breakdown of academic impact, for papers by Hildegonda P. H. Naber Breakdown of academic impact, for papers by Alexis S. Lopez Breakdown of academic impact, for papers by Federica Lorenzi Breakdown of academic impact, for papers by Marina Chan Breakdown of academic impact, for papers by Svetlana Miklikova Breakdown of academic impact, for papers by Jana Plavá Breakdown of academic impact, for papers by Ruping Yan Breakdown of academic impact, for papers by Oihana Iriondo Breakdown of academic impact, for papers by Ramon M. Cabrera
Rankless by CCL
2026